JP2023166395A5 - - Google Patents

Download PDF

Info

Publication number
JP2023166395A5
JP2023166395A5 JP2023130710A JP2023130710A JP2023166395A5 JP 2023166395 A5 JP2023166395 A5 JP 2023166395A5 JP 2023130710 A JP2023130710 A JP 2023130710A JP 2023130710 A JP2023130710 A JP 2023130710A JP 2023166395 A5 JP2023166395 A5 JP 2023166395A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023130710A
Other languages
English (en)
Other versions
JP2023166395A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/036368 external-priority patent/WO2017214282A1/en
Application filed filed Critical
Publication of JP2023166395A publication Critical patent/JP2023166395A/ja
Publication of JP2023166395A5 publication Critical patent/JP2023166395A5/ja
Pending legal-status Critical Current

Links

Claims (3)

  1. 下記の構造を含む抗ヒト上皮成長因子受容体(hEGFR)抗体薬物コンジュゲート(ADC)。
    Figure 2023166395000001
    [式中、Abは、
    配列番号12に記載のアミノ酸配列を含む重鎖CDR3ドメイン、配列番号11に記載のアミノ酸配列を含む重鎖CDR2ドメイン、及び配列番号10に記載のアミノ酸配列を含む重鎖CDR1ドメイン、並びに、
    配列番号8に記載のアミノ酸配列を含む軽鎖CDR3ドメイン、配列番号7に記載のアミノ酸配列を含む軽鎖CDR2ドメイン、及び配列番号6に記載のアミノ酸配列を含む軽鎖CDR1ドメイン
    を含むIgG1抗hEGFR抗体であって、mは2である。]
  2. 抗体が、配列番号9に記載のアミノ酸配列を含む重鎖可変領域、及び配列番号5に記載のアミノ酸配列を含む軽鎖可変領域を含む、請求項1に記載のADC。
  3. 抗体が、配列番号15に記載のアミノ酸配列を含む重鎖、及び配列番号13に記載のアミノ酸配列を含む軽鎖を含む、請求項1又は2に記載のADC。
JP2023130710A 2016-06-08 2023-08-10 抗egfr抗体薬物コンジュゲート Pending JP2023166395A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662347416P 2016-06-08 2016-06-08
US62/347,416 2016-06-08
PCT/US2017/036368 WO2017214282A1 (en) 2016-06-08 2017-06-07 Anti-egfr antibody drug conjugates
JP2018564215A JP2019521106A (ja) 2016-06-08 2017-06-07 抗egfr抗体薬物コンジュゲート
JP2021201460A JP2022058351A (ja) 2016-06-08 2021-12-13 抗egfr抗体薬物コンジュゲート

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021201460A Division JP2022058351A (ja) 2016-06-08 2021-12-13 抗egfr抗体薬物コンジュゲート

Publications (2)

Publication Number Publication Date
JP2023166395A JP2023166395A (ja) 2023-11-21
JP2023166395A5 true JP2023166395A5 (ja) 2024-02-21

Family

ID=59078219

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018564215A Pending JP2019521106A (ja) 2016-06-08 2017-06-07 抗egfr抗体薬物コンジュゲート
JP2021201460A Pending JP2022058351A (ja) 2016-06-08 2021-12-13 抗egfr抗体薬物コンジュゲート
JP2023130710A Pending JP2023166395A (ja) 2016-06-08 2023-08-10 抗egfr抗体薬物コンジュゲート

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018564215A Pending JP2019521106A (ja) 2016-06-08 2017-06-07 抗egfr抗体薬物コンジュゲート
JP2021201460A Pending JP2022058351A (ja) 2016-06-08 2021-12-13 抗egfr抗体薬物コンジュゲート

Country Status (21)

Country Link
US (2) US20190343961A1 (ja)
EP (2) EP4104865A1 (ja)
JP (3) JP2019521106A (ja)
KR (2) KR20230035690A (ja)
CN (4) CN116059201A (ja)
AU (1) AU2017277517A1 (ja)
BR (1) BR112018075636A2 (ja)
CA (1) CA3027178A1 (ja)
CL (2) CL2018003527A1 (ja)
CO (1) CO2018013497A2 (ja)
CR (1) CR20180614A (ja)
DO (2) DOP2018000272A (ja)
EC (1) ECSP19000157A (ja)
IL (3) IL308054A (ja)
MX (2) MX2018015286A (ja)
PE (1) PE20190512A1 (ja)
PH (1) PH12018502602A1 (ja)
RU (1) RU2018147224A (ja)
SG (2) SG10201914060WA (ja)
TW (2) TW202320860A (ja)
WO (1) WO2017214282A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458479B1 (en) 2016-06-08 2020-11-04 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
US20190153108A1 (en) * 2016-06-08 2019-05-23 Abbvie Inc. Anti-egfr antibody drug conjugates
WO2018218004A1 (en) * 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
US11717575B2 (en) 2019-05-20 2023-08-08 Mabplex International Co., Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
EP3972651A2 (en) 2019-05-20 2022-03-30 Novartis AG Mcl-1 inhibitor antibody-drug conjugates and methods of use
KR20210097627A (ko) 2020-01-30 2021-08-09 성균관대학교산학협력단 면역관문 억제제 및 엑소좀 분비 억제제를 포함하는 항체-약물 접합체 및 이를 포함하는 약학적 조성물
EP4153242B1 (en) 2020-05-19 2024-05-15 Les Laboratoires Servier Para-amino-benzyl linkers, process for their preparation and their use in conjugates
EP4251209A1 (en) 2020-11-24 2023-10-04 Novartis AG Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4359440A1 (en) * 2021-06-22 2024-05-01 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibody drug conjugates and uses thereof
CN117580846A (zh) * 2022-04-29 2024-02-20 石药集团中奇制药技术(石家庄)有限公司 具有肝靶向递送效应的化合物及其寡聚核苷酸缀合物
WO2023223097A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody drug conjugates
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1726514A (en) 1926-11-01 1929-08-27 Firm Ferd Liebschner & Sohn Picker for looms
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
PT1522590E (pt) 2000-06-28 2009-10-26 Glycofi Inc Métodos para a produção de glicoproteínas modificadas
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
ES2556641T3 (es) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
DE602004027888D1 (de) 2003-02-20 2010-08-12 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihr
US7375078B2 (en) 2004-02-23 2008-05-20 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AU2005233387B2 (en) 2004-04-15 2011-05-26 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
ES2908458T3 (es) 2005-07-18 2022-04-29 Seagen Inc Conjugados de fármaco-enlazador de beta-glucurónido
MX2008009956A (es) 2006-02-02 2008-12-12 Syntarga Bv Analogos de cc-1065 solubles en agua y sus conjugados.
EP2217283A2 (en) 2007-11-28 2010-08-18 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
KR20120057588A (ko) 2009-05-28 2012-06-05 메르사나 테라퓨틱스, 인코포레이티드 가변 속도 방출 링커를 포함하는 폴리알 약물 접합체
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
CN103987711B (zh) * 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
KR20140139480A (ko) 2011-12-05 2014-12-05 이제니카 바이오테라퓨틱스, 인크. 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법
WO2013096901A1 (en) 2011-12-23 2013-06-27 Mersana Therapeutics, Inc. Pharmaceutical formulations for fumagillin derivative-phf conjugates
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
CN108465112B (zh) 2012-05-15 2022-04-29 西雅图基因公司 自稳定接头偶联物
US20140017265A1 (en) 2012-07-05 2014-01-16 Mersana Therapeutics, Inc. Terminally Modified Polymers and Conjugates Thereof
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
KR20220025946A (ko) * 2014-03-21 2022-03-03 애브비 인코포레이티드 항-egfr 항체 및 항체 약물 접합체
BR112017012342A2 (pt) * 2014-12-09 2018-02-27 Abbvie Inc compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
WO2016094509A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
CN113209306A (zh) * 2014-12-09 2021-08-06 艾伯维公司 具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物

Similar Documents

Publication Publication Date Title
JP2023166395A5 (ja)
JP2020039360A5 (ja)
JP2009225799A5 (ja)
JP2009532336A5 (ja)
JP2022031635A5 (ja)
JP2009517057A5 (ja)
JP2022191301A5 (ja)
JP2004248677A5 (ja)
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
RU2012119788A (ru) Связывающие il-1 белки
TW201819408A (zh) 抗pd-1抗體及組成物
FI2155783T4 (fi) Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
EP2336183A3 (en) Antibodies against CCR5 and uses thereof
JP2010511388A5 (ja)
EP2426146A3 (en) Anti-human IL-21 monoclonal antibodies
RU2602878C3 (ru) Конъюгаты "производное калихеамицина-носитель"
JP2010526028A5 (ja)
RU2011101969A (ru) Антитела к человеческому интерлейкину-20
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
JP2010536384A5 (ja)
JP2003528052A5 (ja)
RU2003107564A (ru) Антитела к человеческому il-1бета
JP2007097598A5 (ja)
RU2003100512A (ru) Антитела к человеческому мср-1
RU2009149294A (ru) Антиген-связывающие белки, нацеленные на orf0657n s.aureus